Bone Abstracts

The objective of this investigation was to compare bone mineral density (BMD) attained from dual-energy X-ray DXA with speed of sound (SOS) data attained from a Beam-Med Omnisense multisite quantitative ultrasound (mQUS) in a large sample of randomly-selected community-based individuals from the Canadian Multicentre Osteoporosis Study (CaMOS). A total of 1177 men and 2949 women were assessed with mQUS at the distal radius, tibia, and phalanx sites as part of the Canadian Multi...

This investigation sought to assess the relationship between physical activity (PA) and estimated bone stiffness as assessed by multisite quantitative ultrasound (mQUS) in a large cohort. A total of 1177 men and 2949 women were assessed with mQUS (Beam-Med Omnisense quantitative ultrasound; Isreal) at the distal radius, tibia, and phalanx sites as part of the Canadian Multicentre Osteoporosis Study (clinical sites included Saskatoon, Calgary, Hamilton, Quebec City, Halifax and...

This investigation sought to assess the relationship between vitamin D and calcium intake and estimated bone stiffness as assessed by multisite quantitative ultrasound (mQUS) in a large cohort. A total of 1177 men and 2949 women were assessed with mQUS (Beam-Med Omnisense quantitative ultrasound; Isreal) at the distal radius, tibia, and phalanx sites as part of the Canadian Multicentre Osteoporosis Study (clinical sites included Saskatoon, Calgary, Hamilton, Quebec City, Halif...

Introduction: Paget’s disease of bone (PDB) has an autosomal-dominant mode of inheritance in one-third of cases. The germinal SQSTM1/P392L mutation is the most frequent mutation, present in 40% of patients with a familial form of PDB, and 8% of unrelated patients. Fibrous dysplasia (FD) is a rare bone disorder, mono or polyostotic, caused by post-zygotic mutations in GNAS gene, for which a PCR-clamping method was developed to ease their detection and avo...

Background: Atypical femur fractures (AFF) arise in the subtrochanteric and diaphyseal regions. Because of this unique distribution, we hypothesized that patients with AFF demonstrate specific geometrical variations of their femur whereby baseline tensile forces applied to the lateral cortex are higher and might favor the appearance of these rare stress fractures, when exposed to bisphosphonates.Methods: Subjects who sustained AFF, as defined by the ASBM...

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

Low fracture (FX) incidence has been demonstrated in women with postmenopausal osteoporosis (PMO) treated with DMAb for up to 10 years in the FREEDOM extension [Bone ASBMR 2015]. Bone biopsy-based assessment of DMAb’s effects at the tissue level has demonstrated a low remodelling rate consistent with DMAb’s mechanism of action (Reid JBMR 2010; Brown JBMR 2014). From FREEDOM, we report the effects of DMAb on bone matrix mineralization in women who un...

DMAb increases BMD and reduces bone resorption and risk of vertebral, nonvertebral and hip fractures in women with PMO. Transiliac crest bone biopsies in 47 subjects treated with DMAb for 1–3 years showed reduced bone turnover vs 45 Pbo-treated subjects, which reversed on treatment cessation. Since bone turnover reduction is sustained and fracture incidence low over 6 years’ DMAb treatment, we evaluated DMAb’s effects on tissue-level remodelling in the FREEDOM E...

see PP357....

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...